Aim: 1) To assess the frequency of specialist PCC referrals in our GUMOC. 2) To analyze the impact of PCC referrals on the symptomatology of patients. Methods: 239 consecutive pts were collected from a retrospective review of GUMOC records in Roswell Park Cancer Institute from 12/1/2013 to 2/28/2014. This group of pts was used to assess the frequency of PCC referral. Pts were divided into two armsArm A= GUMOC pts referred to PCC; Arm B: GUMOC pts not referred to PCC. To be able to detect a 15% between the two arms at 95% significance, 37 additional pts (who were already being seen at GUMOC) were collected from retrospective review of PCC records over 9/1/2013 to 2/28/2014. Total 276 patients were divided into Arm A (n = 49), Arm B (n = 227 patients). Arm B includes 12 pts from GUMOC records and 37 pts from PCC records. Data for baseline symptom score and 4-week follow up symptom scores were collected. A palliative care screening tool (retrieved from Center to Advance Palliative care [CAPC] website) was used to assign a palliative care screening score (PCSS) to all study patients. Chi square test and T-test used respectively for categorical variables and numerical variables. Results: Out of the 239 initially collected GUMOC patients, 5% were referred to PCC. 10% (n = 24) had PCSS score of ≥ 4, and 33% pts with PCSS ≥ 4 were referred to PCC. Baseline symptoms, ECOG status (2-3) and cancer stage (locally advanced or stage 4) were more advanced in the Arm A vs. Arm B ( p = 0.02, p < 0.01, p < 0.01 respectively). On comparing the symptom score change from baseline to 4-week follow-up, significant improvement occurred in Arm A
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